BioLife Solutions Announces Record Revenue of $2.2 Million in First Quarter of 2013
Company Achieves Operating Income of $0.2 Million Driven by Organic Growth, Licensing Revenue
BOTHELL, Wash., May 14, 2013 /PRNewswire/ — BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced record revenue for the first quarter of 2013 of $2.2 million, including license revenue of $0.6 million, representing 5% sequential growth over the fourth quarter of 2012 and 158% growth over the first quarter of 2012.
Mike Rice, Chief Executive Officer, said, “Overall, we are pleased with our performance in the first quarter of 2013. We continued to meet demand from our contract manufacturing customers and have expanded our production and warehouse facilities to support growth in this service revenue line. We also negotiated a new intellectual property license agreement with a leading regenerative medicine company that resulted in license revenue of $0.6 million in the quarter. This is continued validation of the unique and critical value proposition of our proprietary technologies. Core product sales to the regenerative medicine market were lower than expected, highlighting uneven product ordering patterns from customers who are developing these novel therapies, due to the pace of product evaluations, adoption and clinical trials.”
The regenerative medicine market is expected to grow to more than $35 billion by 2019, according to TriMark Publications’ newly published “Regenerative Medicine Markets” report. BioLife’s addressable portion of the market is the demand for reagents used to store, ship and freeze source material and manufactured doses of cell-based products and therapies.
Rice continued, “We estimate that our HypoThermosol(®) cell/tissue storage medium and CryoStor(®) cryopreservation freeze media products are used in more than fifty clinical trial-stage cell and tissue-based therapies in the regenerative medicine field, any one of which could generate $1 million per year in revenue, if regulatory and marketing approvals are obtained by our customers, and their products are commercially successful.”
First Quarter 2013 Financial Results
Total revenue for the first quarter of 2013 was $2.2 million, compared to $0.8 million in the same period of 2012. The increase of 158% from 2012 to 2013 was due primarily to increased license revenue, contract manufacturing revenue and higher sales to the Company’s network of distributors, offset by lower direct product sales to the regenerative medicine market. Sales to this segment are uneven due to the pace of customer product evaluations, adoption and clinical trials.
During the first quarter of 2013, the Company negotiated a new intellectual property license agreement that provides one customer with limited access to BioLife’s intellectual property under certain conditions. This customer paid upfront fees for the specific rights and there are no future performance obligations. The upfront fee of $0.5 million was recognized as revenue during the quarter and $0.1 million in deferred revenue associated with this customer was recognized as all future performance obligations associated with the previous license agreements were cancelled with the agreement signed in the first quarter of 2013.
Gross margin as a percentage of revenue decreased to 52.1% in the first quarter of 2013 compared to 58.6% for the same period in 2012 due primarily to the increase in contract manufacturing product sales, which has a higher cost of sales, compared to core product sales, offset by recognition of the license revenue during the quarter with no associated costs.
Operating expenses in the first quarter of 2013 were $0.9 million compared with $0.7 million in the first quarter of 2012. This increase was primarily attributable to additional personnel costs that commenced in the second quarter of 2012, higher corporate costs, higher depreciation and rent costs related to the new facility, and higher office-related expenses.
For the first quarter of 2013, the Company reported operating income of $0.2 million compared to operating loss of $0.2 million in the first quarter of 2012. Net loss was $(7,176), or $(0.00) per share for the first quarter of 2013, compared to a loss of $0.3 million or $(0.00) per share in the first quarter of 2012.
Outlook for 2013
The Company continues to expect the following 2013 results:
- Revenue in the range of $6.5 million to $7.0 million, driven by continued increases in sales to existing core product and contract manufacturing customers, the addition of new customers in the regenerative medicine market as customers continue to move their cell and tissue-based therapies and products through the clinical trial and regulatory approval processes, and continued focus on sales through existing distribution network. The Company does not anticipate additional licensing transactions similar to that concluded in the first quarter.
- Gross margin as a percentage of revenue of approximately 38% – 41% in 2013, with fluctuation occurring as a result of changes in the mix of core product sales and contract manufacturing services revenue.
- Operating expense increases of 10% – 20% over 2012, with increases expected in all areas, primarily in personnel related costs.
- Operating and net income (loss) improvements over 2012.
BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions for cells, tissues, and organs. The Company’s proprietary HypoThermosol(®) and CryoStor(®) platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife’s products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife’s enabling technology provides academic and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities and potential regulatory approvals and commercial success of our customers’ products. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
Media Relations: Investor Relations: Len Hall Matt Clawson Allen & Caron Inc Allen & Caron Inc (949) 474-4300 (949) 474-4300 email@example.com firstname.lastname@example.org
BioLife Solutions, Inc. Statement of Operations Three Months Ended March 31, --------------- 2013 2012 ---- ---- Revenue Product sales $1,550,845 $830,880 Licensing revenue 609,167 5,000 ------- ----- Total revenue 2,160,012 835,880 Cost of product sales 1,034,528 346,129 --------- ------- Gross profit 1,125,484 489,751 Operating expenses Research and development 105,968 116,521 Sales and marketing 202,758 73,381 General and administrative 624,427 479,113 Total operating expenses 933,153 669,015 ------- ------- Operating income (loss) 192,331 (179,264) ------- -------- Other income (expenses) Other income -- 88,272 Interest expense (185,555) (178,777) Loss on disposal of equipment -- (63) Amortization of deferred financing costs (13,952) (27,045) Total other income (expenses) (199,507) (117,613) Net Loss $(7,176) $(296,877) Basic and diluted net loss per common share $(0.00) $(0.00) Basic and diluted weighted average common shares used to calculate net loss per common share 69,873,598 69,679,854 ========== ==========
Selected Balance Sheet Data March 31, December 31, 2013 2012 ---- ---- Cash and cash equivalents $61,523 $196,478 Accounts receivable 976,157 600,153 Inventories 676,438 656,397 Total current assets 1,915,919 1,627,759 Total current liabilities 1,473,479 1,365,338 Promissory notes payable, related parties 10,603,127 10,603,127 Accrued interest, related parties 2,944,946 2,759,391 Total liabilities 15,819,636 15,655,852 Total shareholders' equity (deficiency) (12,400,359) (12,486,023)
Selected Cash Flow Data Three Months Ended March 31, 2013 2012 ---- ---- Cash used in operating activities $(126,476) $(74,823) Cash used in investing activities (33,937) (46,517) Cash provided by financing activities 25,458 175,000 Net increase (decrease) in cash and equivalents (134,955) 53,660
SOURCE BioLife Solutions, Inc.